The Next Big Step For Cannabis Companies July 27, 2018 - OilPrice.com There's a new type of investment now available to marijuana companies. It’s one with even better potential than we’ve seen so far. And, with the global marijuana sector projected to grow to $57 billion over the next 10 years... This could be the one company that has the right focus. But it's not just any company... It's a marijuana incubator (and much more). And that's what makes it so compelling. Scythian Biosciences Corp. (TSXV: SCYB.V; OTC:SCCYF) is a tiny company with a big secret. It’s the only truly global cannabis investment company... PLUS an incubator for marijuana ventures and research throughout the world. And now, it’s got millions of dollars in seed money from investors including Aphria Inc. (OTCMKTS: APHQF), a $2.952 billion behemoth and one of the biggest sharks in the cannabis sector. [BREAKING: Aphria Inc. ups stake in Scythian Bioscences Corp. in a $193 million-dollar deal. This effectively turns Scythian Biosciences Corp. into Aphria’s incubator. Aphria, a $3 billion market cap member of the S&P/TSX Composite Index, is the largest cannabis company in Canada.] Everyone’s been paying attention to the North American weed market… but they’ve been missing the global picture. 1.37 billion people in Europe and Latin America could soon gain access to legal marijuana. And one company has been getting in on this trend before others... The team behind Scythian Biosciences Corp. (TSXV: SCYB.V; OTC:SCCYF) is poised to grow globally... get access to the best deals... and bring the profits home. Here are four reasons Scythian Biosciences Corp. looks to continue to great success. # 1 Tipping Point for a $57 Billion Market… Cannabis has been one of the biggest stories of 2018… but few have grasped the real size of the opportunity. The multi-billion move of money from the informal economy (illegal one) to the legal one is happening at a rapid pace. It’s a once-in-a-lifetime “green” gold rush. A report from Arcview Market Research and BDS Analytics found cannabis sales accounted for $9.5 billion in consumer spending. The total size of the global cannabis market is estimated to reach $32 billion by 2022 and $57 billion by 2027, and Scythian is on the ground floor, enjoying a “first mover” approach that will position it ahead of the pack. The bulk of pot sales are in the United States, which at the moment has a patchwork of state regulations dictating how marijuana can be sold and consumed legally. But North American pot consumption is bound to rise rapidly, led by groundbreaking Canadian legalization this year. Canadians spent $5.7 billion on cannabis products in 2017, but with recreational pot now about to become legal, that figure could explode as millions of new users could start lighting up legally. Across North America, marijuana is having its best year ever. Support for legalizing weed across the U.S. is at its highest level in years—polls find as much as 80 percent in favor. And the limited space for medical marijuana is blossoming into a much broader market, one that includes recreational marijuana use and marijuana-based pharmaceutical products. The FDA, for instance, just approved the first ever drug based on cannabis. States are rushing towards legalization: super-conservative Oklahoma, for instance, just legalized medical marijuana, becoming the 30th state to do so. States like Oklahoma are desperate for tax revenue…the kind that a new green pot industry could generate. States like Vermont, Michigan and California are lining up to expand to recreational use and make a killing in the process. With such momentum, $57 billion in 10 years may be a conservative estimate. The greener North America gets, the bigger the opportunity in pot becomes. # 2…And it Could Become Much Bigger – GLOBALLY -- than $57 Billion North America is driving an investment surge in the cannabis sector. But the opportunity is even bigger than the first wave of companies has realized. Scythian Biosciences Corp. (TSXV: SCYB.V; OTC:SCCYF) is unique because it taps into the global opportunity… something that firms focused on North America have overlooked. Scythian‘s model, gains exposure to America... plus a larger global cannabis market. One such avenue for exposure is in Latin America, where Scythian has already laid down a foundation. The company’s acquisition target has government approval to support low-cost distributors based in Colombia and Jamaica. Scythian is on the verge of acquiring Colcanna SAS, which has just received licenses from the Colombian government to cultivate, extract, produce and research medical cannabis. In Argentina, Scythian’s soon to be acquired target MMJ International is the only company to receive government approval. And this subsidiary, and Colcanna SAS, together with other South American assets that Scythian has on the block to buy, are going to be flipped to Aphria for $193 million in cash and stock: a very big markup on assets that haven’t been paid for yet. And the European market could be even bigger. The continent has twice as many people as the U.S. and could provide double the sales, as restrictive laws fall like dominoes. Scythian has a plan in place to tap into the European market, laying a foundation in key countries across the continent. The UK, where new cannabis laws could be just around the corner, could be a huge opportunity—a country where informal economy marijuana sales totaled $3.46 billion and counted 3 million users. The company is laying the foundation for a global marijuana boom, and when European laws change, Scythian will be in prime position to seize a chunk of the market there too. # 3 Marijuana Sector Diversification... PLUS Incubator Upside Scythian’s (TSXV: SCYB.V; OTC:SCCYF) plan is bigger than just production and distribution. The company invests in every part of the cannabis supply chain. Its biggest opportunity is in Argentina, where it’s just agreed to sell its target assets to Aphria Inc., the major Canadian marijuana producer. Aphria pumped $14 million into Scythian to help it tap into Latin America, the expected next major growth area in cannabis. With Aphria’s and other investors’ money, Scythian is setting out to incubate marijuana distributors across the world—building markets that both Aphria and Scythian can exploit with Canadian pot. There are lots of different opportunities for Scythian to hit it big. A consumer marijuana product, a “Coca Cola” for pot smokers, could let it tap into the recreational market. Scythian is always on the hunt for opportunities like this. A “Pfizer,” style medical marijuana product, on the other hand, would let it access the medical marijuana industry, one that could grow by leaps and bounds if more marijuana-based drugs receive approval from the FDA. Scythian has been researching medicinal marijuana and could possibly come up with something big. Beyond distribution, Scythian is incubating marijuana research ventures at the University of Miami, University College Dublin, Universidad de la Plata and the University of West Indies. From these investments, Scythian could acquire lucrative new patents for marijuana products—from cannabis oils to new strains of pot to pill-based THC consumables. Scythian could acquire profitable patents, then watch the money roll in from licensing. And not only that, they’re creating a range of market consumer brands that can extend into every branch of the marijuana business and are working to make them the leading brands in their product lines. #4 Global Cannabis Market Few people understand the scope of what’s going on behind the scenes at this little-known company but that’s about to change. Aphria has pumped $14 million into the company, supporting their expansion through Latin America and Europe. And Aprhia is one of the biggest players in the marijuana space: a $2.952 billion company that dominates medical marijuana and is bound to profit from Canada’s legalization. The cannabis market may have attracted some big money, but NOBODY can realize the potential of the global weed market… like Scythian can. So, rather than banking on fly-by-wire growers in North America, where markets might get saturated with pot, savvy companies should look abroad, where billions of customers remain underserved and where legalization legislation is probably not far off. As many as 1.37 billion people in Europe and Latin America may soon be free to shop for pot. And Scythian wants to bring it to them. Other companies looking to take marijuana global:Cronos Group Inc (TSX:CRON) is another Toronto-based cannabis company with a lot of ambition. The company has prioritized its production acquisitions in order to provide geographically diverse products. Loaded with values, this company is comprised of passionate and focused employees. One of the primary objectives of Cronos Group is to destigmatize the medical use of marijuana and bring medicine to those who need it. Cronos Group has made it their priority to lead as an example for the industry, and provide the best care possible to the community. Hydropothecary Corp (TSX:HEXO) is a another heavy hitter in Canada’s cannabis scene. With former BC Health Minister Dr. Terry Lake as the VP of Corporate Social Responsibility, and the well-versed Ed Chaplin, who has raised millions for his previous ventures, as the Chief Financial Officer, the company is sure to have a bright future ahead. With 4 primary products, including Canada’s only peppermint flavored medical cannabis oil sublingual mist, Hydropothecary has chosen quality over quantity. Offering patients the ability to administer their medication in a smoke-free format provides users with an option that is not available just anywhere. Beleave (CSE:BE): Beleave is a biotech company focused on the production of medical marijuana in Canada. Its wholly-owned subsidiary, First Access, applied for a pre-license inspection in March 2017. Beleave became Cannabis Wheaton’s fifth production partner in May and the parties will work cooperatively to identify an appropriate second site to be acquired and developed by a newly formed special purpose subsidiary of Beleave ("NewCo"). The proposed second site is expected to be located in Ontario and will be designed to accommodate an estimated 200,000 square feet of cultivation space. Aphria (TSX:APH) is a Canada-based cannabis company which focuses on the production, sales, and distribution of legal marijuana. The company’s business model focuses primarily on online sales, which is perfect for its patients. A simple point and click and the medication will arrive at the patient’s in no time. Aphria’s products are developed to treat to a variety of different patients and symptoms. The company offers several smoke free medications for those who are unable to consume the products in that manner. Aphria also produces low-THC products for patients who are more sensitive to marijuana’s psychoactive properties. Supreme Pharmaceuticals Inc (TSXV:FIRE): Supreme Pharmaceuticals Inc is engaged in production and sale of medical marijuana. The company is a cultivator and distributor of sun-grown cannabis through its wholly-owned subsidiary 7ACRES. The Company is focused on the wholesale sector of the medical cannabis market in Canada and operates an approximately 342,000 square foot greenhouse facility located in Kincardine, Ontario. Supreme had its license term extended for an additional two years and license now permits the company to store up to $150 million of cannabis products at any given time. The company is expected to produce 10,000 grams of cannabis in 2017 with an estimated value of $35 million. **IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY** Notice for Forward-Looking Information Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes information relating to Scythian’s proposed acquisition of Marigold, MMJ Colombia, ABP and ColCanna; the expected sale of these companies to Aphria and resulting receipt of $193M from Aphria; that cannabis use and sales will grow as predicted; Scythian’s intended acquisition of various foreign assets and potential sale to Aphria; that Scythian will be in a prime position in the UK and Europe to take a substantial portion of the cannabis market when laws permit; that Scythian can create its own “ecosystem” – from plant to product – in each territory it enters; its plans to incubate projects in various locations throughout the world; it could be granted licensable patents; and that it’s traumatic brain injury solutions will be accepted by medical practitioners. Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sale are not obtained or are obtained subject to conditions that are not anticipated; that a condition to the completion of the intended acquisitions or sale may not be satisfied; construction delays and costs overruns; potential future competition in the markets Scythian operates; that Scythian’s technology may not achieve the expected results and its accomplishments may be limited; that Scythian may not establish a market for its services as expected; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may change; technological change may result in Scythian’s solutions not be the best or cheapest available; Scythian not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; Scythian’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies; Scythian’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; changes in laws; and regulatory risks relating to Scythian’s business, financings and strategic acquisitions. DISCLAIMERS PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Oilprice.com, Advanced Media Solutions Ltd, and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by Scythian Fifty-eight thousand three hundred thirty three US dollars for this landing page and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically: This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by Scythian to conduct investor awareness advertising and marketing for Scythian. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct. SHARE OWNERSHIP. The owner of Oilprice.com owns shares and/or stock options of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The owner of Oilprice.com will not notify the market when it decides to buy or sell shares of this issuer in the market. The owner of Oilprice.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions. RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.
The Next Big Step For Cannabis Companies July 27, 2018 - OilPrice.com There's a new type of investment now available to marijuana companies. It’s one with even better potential than we’ve seen so far. And, with the global marijuana sector projected to grow to $57 billion over the next 10 years... This could be the one company that has the right focus. But it's not just any company... It's a marijuana incubator (and much more). And that's what makes it so compelling. Scythian Biosciences Corp. (TSXV: SCYB.V; OTC:SCCYF) is a tiny company with a big secret. It’s the only truly global cannabis investment company... PLUS an incubator for marijuana ventures and research throughout the world. And now, it’s got millions of dollars in seed money from investors including Aphria Inc. (OTCMKTS: APHQF), a $2.952 billion behemoth and one of the biggest sharks in the cannabis sector. [BREAKING: Aphria Inc. ups stake in Scythian Bioscences Corp. in a $193 million-dollar deal. This effectively turns Scythian Biosciences Corp. into Aphria’s incubator. Aphria, a $3 billion market cap member of the S&P/TSX Composite Index, is the largest cannabis company in Canada.] Everyone’s been paying attention to the North American weed market… but they’ve been missing the global picture. 1.37 billion people in Europe and Latin America could soon gain access to legal marijuana. And one company has been getting in on this trend before others... The team behind Scythian Biosciences Corp. (TSXV: SCYB.V; OTC:SCCYF) is poised to grow globally... get access to the best deals... and bring the profits home. Here are four reasons Scythian Biosciences Corp. looks to continue to great success. # 1 Tipping Point for a $57 Billion Market… Cannabis has been one of the biggest stories of 2018… but few have grasped the real size of the opportunity. The multi-billion move of money from the informal economy (illegal one) to the legal one is happening at a rapid pace. It’s a once-in-a-lifetime “green” gold rush. A report from Arcview Market Research and BDS Analytics found cannabis sales accounted for $9.5 billion in consumer spending. The total size of the global cannabis market is estimated to reach $32 billion by 2022 and $57 billion by 2027, and Scythian is on the ground floor, enjoying a “first mover” approach that will position it ahead of the pack. The bulk of pot sales are in the United States, which at the moment has a patchwork of state regulations dictating how marijuana can be sold and consumed legally. But North American pot consumption is bound to rise rapidly, led by groundbreaking Canadian legalization this year. Canadians spent $5.7 billion on cannabis products in 2017, but with recreational pot now about to become legal, that figure could explode as millions of new users could start lighting up legally. Across North America, marijuana is having its best year ever. Support for legalizing weed across the U.S. is at its highest level in years—polls find as much as 80 percent in favor. And the limited space for medical marijuana is blossoming into a much broader market, one that includes recreational marijuana use and marijuana-based pharmaceutical products. The FDA, for instance, just approved the first ever drug based on cannabis. States are rushing towards legalization: super-conservative Oklahoma, for instance, just legalized medical marijuana, becoming the 30th state to do so. States like Oklahoma are desperate for tax revenue…the kind that a new green pot industry could generate. States like Vermont, Michigan and California are lining up to expand to recreational use and make a killing in the process. With such momentum, $57 billion in 10 years may be a conservative estimate. The greener North America gets, the bigger the opportunity in pot becomes. # 2…And it Could Become Much Bigger – GLOBALLY -- than $57 Billion North America is driving an investment surge in the cannabis sector. But the opportunity is even bigger than the first wave of companies has realized. Scythian Biosciences Corp. (TSXV: SCYB.V; OTC:SCCYF) is unique because it taps into the global opportunity… something that firms focused on North America have overlooked. Scythian‘s model, gains exposure to America... plus a larger global cannabis market. One such avenue for exposure is in Latin America, where Scythian has already laid down a foundation. The company’s acquisition target has government approval to support low-cost distributors based in Colombia and Jamaica. Scythian is on the verge of acquiring Colcanna SAS, which has just received licenses from the Colombian government to cultivate, extract, produce and research medical cannabis. In Argentina, Scythian’s soon to be acquired target MMJ International is the only company to receive government approval. And this subsidiary, and Colcanna SAS, together with other South American assets that Scythian has on the block to buy, are going to be flipped to Aphria for $193 million in cash and stock: a very big markup on assets that haven’t been paid for yet. And the European market could be even bigger. The continent has twice as many people as the U.S. and could provide double the sales, as restrictive laws fall like dominoes. Scythian has a plan in place to tap into the European market, laying a foundation in key countries across the continent. The UK, where new cannabis laws could be just around the corner, could be a huge opportunity—a country where informal economy marijuana sales totaled $3.46 billion and counted 3 million users. The company is laying the foundation for a global marijuana boom, and when European laws change, Scythian will be in prime position to seize a chunk of the market there too. # 3 Marijuana Sector Diversification... PLUS Incubator Upside Scythian’s (TSXV: SCYB.V; OTC:SCCYF) plan is bigger than just production and distribution. The company invests in every part of the cannabis supply chain. Its biggest opportunity is in Argentina, where it’s just agreed to sell its target assets to Aphria Inc., the major Canadian marijuana producer. Aphria pumped $14 million into Scythian to help it tap into Latin America, the expected next major growth area in cannabis. With Aphria’s and other investors’ money, Scythian is setting out to incubate marijuana distributors across the world—building markets that both Aphria and Scythian can exploit with Canadian pot. There are lots of different opportunities for Scythian to hit it big. A consumer marijuana product, a “Coca Cola” for pot smokers, could let it tap into the recreational market. Scythian is always on the hunt for opportunities like this. A “Pfizer,” style medical marijuana product, on the other hand, would let it access the medical marijuana industry, one that could grow by leaps and bounds if more marijuana-based drugs receive approval from the FDA. Scythian has been researching medicinal marijuana and could possibly come up with something big. Beyond distribution, Scythian is incubating marijuana research ventures at the University of Miami, University College Dublin, Universidad de la Plata and the University of West Indies. From these investments, Scythian could acquire lucrative new patents for marijuana products—from cannabis oils to new strains of pot to pill-based THC consumables. Scythian could acquire profitable patents, then watch the money roll in from licensing. And not only that, they’re creating a range of market consumer brands that can extend into every branch of the marijuana business and are working to make them the leading brands in their product lines. #4 Global Cannabis Market Few people understand the scope of what’s going on behind the scenes at this little-known company but that’s about to change. Aphria has pumped $14 million into the company, supporting their expansion through Latin America and Europe. And Aprhia is one of the biggest players in the marijuana space: a $2.952 billion company that dominates medical marijuana and is bound to profit from Canada’s legalization. The cannabis market may have attracted some big money, but NOBODY can realize the potential of the global weed market… like Scythian can. So, rather than banking on fly-by-wire growers in North America, where markets might get saturated with pot, savvy companies should look abroad, where billions of customers remain underserved and where legalization legislation is probably not far off. As many as 1.37 billion people in Europe and Latin America may soon be free to shop for pot. And Scythian wants to bring it to them. Other companies looking to take marijuana global:Cronos Group Inc (TSX:CRON) is another Toronto-based cannabis company with a lot of ambition. The company has prioritized its production acquisitions in order to provide geographically diverse products. Loaded with values, this company is comprised of passionate and focused employees. One of the primary objectives of Cronos Group is to destigmatize the medical use of marijuana and bring medicine to those who need it. Cronos Group has made it their priority to lead as an example for the industry, and provide the best care possible to the community. Hydropothecary Corp (TSX:HEXO) is a another heavy hitter in Canada’s cannabis scene. With former BC Health Minister Dr. Terry Lake as the VP of Corporate Social Responsibility, and the well-versed Ed Chaplin, who has raised millions for his previous ventures, as the Chief Financial Officer, the company is sure to have a bright future ahead. With 4 primary products, including Canada’s only peppermint flavored medical cannabis oil sublingual mist, Hydropothecary has chosen quality over quantity. Offering patients the ability to administer their medication in a smoke-free format provides users with an option that is not available just anywhere. Beleave (CSE:BE): Beleave is a biotech company focused on the production of medical marijuana in Canada. Its wholly-owned subsidiary, First Access, applied for a pre-license inspection in March 2017. Beleave became Cannabis Wheaton’s fifth production partner in May and the parties will work cooperatively to identify an appropriate second site to be acquired and developed by a newly formed special purpose subsidiary of Beleave ("NewCo"). The proposed second site is expected to be located in Ontario and will be designed to accommodate an estimated 200,000 square feet of cultivation space. Aphria (TSX:APH) is a Canada-based cannabis company which focuses on the production, sales, and distribution of legal marijuana. The company’s business model focuses primarily on online sales, which is perfect for its patients. A simple point and click and the medication will arrive at the patient’s in no time. Aphria’s products are developed to treat to a variety of different patients and symptoms. The company offers several smoke free medications for those who are unable to consume the products in that manner. Aphria also produces low-THC products for patients who are more sensitive to marijuana’s psychoactive properties. Supreme Pharmaceuticals Inc (TSXV:FIRE): Supreme Pharmaceuticals Inc is engaged in production and sale of medical marijuana. The company is a cultivator and distributor of sun-grown cannabis through its wholly-owned subsidiary 7ACRES. The Company is focused on the wholesale sector of the medical cannabis market in Canada and operates an approximately 342,000 square foot greenhouse facility located in Kincardine, Ontario. Supreme had its license term extended for an additional two years and license now permits the company to store up to $150 million of cannabis products at any given time. The company is expected to produce 10,000 grams of cannabis in 2017 with an estimated value of $35 million. **IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY** Notice for Forward-Looking Information Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes information relating to Scythian’s proposed acquisition of Marigold, MMJ Colombia, ABP and ColCanna; the expected sale of these companies to Aphria and resulting receipt of $193M from Aphria; that cannabis use and sales will grow as predicted; Scythian’s intended acquisition of various foreign assets and potential sale to Aphria; that Scythian will be in a prime position in the UK and Europe to take a substantial portion of the cannabis market when laws permit; that Scythian can create its own “ecosystem” – from plant to product – in each territory it enters; its plans to incubate projects in various locations throughout the world; it could be granted licensable patents; and that it’s traumatic brain injury solutions will be accepted by medical practitioners. Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sale are not obtained or are obtained subject to conditions that are not anticipated; that a condition to the completion of the intended acquisitions or sale may not be satisfied; construction delays and costs overruns; potential future competition in the markets Scythian operates; that Scythian’s technology may not achieve the expected results and its accomplishments may be limited; that Scythian may not establish a market for its services as expected; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may change; technological change may result in Scythian’s solutions not be the best or cheapest available; Scythian not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; Scythian’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies; Scythian’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; changes in laws; and regulatory risks relating to Scythian’s business, financings and strategic acquisitions. DISCLAIMERS PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Oilprice.com, Advanced Media Solutions Ltd, and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by Scythian Fifty-eight thousand three hundred thirty three US dollars for this landing page and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically: This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by Scythian to conduct investor awareness advertising and marketing for Scythian. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct. SHARE OWNERSHIP. The owner of Oilprice.com owns shares and/or stock options of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The owner of Oilprice.com will not notify the market when it decides to buy or sell shares of this issuer in the market. The owner of Oilprice.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions. RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.